A new experimental vaccine could offer protection not only against many variants of SARS-CoV-2, but also other sarbecoviruses that could spill over from animals to humans.

Bullish option flow detected in Novavax (NVAX) with 15,743 calls trading, 1.7x expected, and implied vol increasing over 2 points to 73.97%.

SINGAPORE - People who are eligible for the Novavax Covid-19 vaccine can go to selected clinics from Jan 24 to April 30 for ...

SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

The CDC ACIP recommends 2 doses of the 2024-2025 COVID-19 vaccine for those age 65+ years and 2 or more doses for immunocompromised individuals.

We recently compiled a list of the 10 Under-the-Radar Stocks with Massive Upside for 2025. In this article, we are going to ...

The CDC issued a health advisory Thursday recommending that hospitalized patients who have tested positive for influenza be ...

Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

With its significant cash infusions from offloading its COVID assets, Novavax had just over $1 billion as it exited Q3, 2024.

New York Amsterdam News | Word In Black (WIB) - With the triad of respiratory viruses present in our day-to-day, it ...